A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT

NCT03368664 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

16

Enrollment

INDUSTRY

Sponsor class

Stopped Enrolment formally closed earlier than planned due to recruitment challenges.

Conditions

Multiple Sclerosis

Interventions

DRUG: Alemtuzumab GZ402673
DRUG: Glatiramer acetate
DRUG: Beta-Interferon
DRUG: Methylprednisolone
DRUG: Ranitidine
DRUG: Ceterizine
DRUG: Dexchlorpheniramine
DRUG: Paracetamol
DRUG: Acyclovir
DRUG: Prednisolone
DRUG: Diphenydramine
DRUG: Other H1 antagonist
DRUG: Other H1 antagonist

Sponsor

Genzyme, a Sanofi Company